9.8% reported weight loss · 2.4% loss with placebo · 44 weeks
180 mg once daily
Chinese adults with overweight or obesity without diabetes
Primary week 44 analysis including discontinuation and other obesity therapies. China obesity phase 3 positive; global phase 2 ongoing with 2027 data planned.
Safety context
Most reported adverse events were mild or moderate gastrointestinal events.
Limitations: Week 50 11.1% is ad hoc efficacy analysis, not primary TP. Sponsor topline.
Adjusted repeated-measures estimate from the published phase 2 trial.
Safety context
Across active arms, adverse events occurred in 71.8–84.6%, mainly mild/moderate gastrointestinal events. Nine participants had level 1 hypoglycemia; no level 2 or 3 events were reported.
Limitations: Highest dose shown; the 60 mg arm had a numerically larger decrease (1.82 pp). Dose response was not monotonic.
No approved trade name verified as of September 13, 2026; the compound name and development codes are not trade names.
Hengrui Pharma · Originator and Greater-China developer.; Kailera Therapeutics · Exclusive development and commercialization licensee outside China, Hong Kong, Macau and Taiwan.
Uses, doses and availability depend on the formulation, indication and country. Study doses below describe research; they are not prescribing instructions.
Chemical connectivity and stereochemistry of Safiglipron.
Shown: Active compound as represented in the named PubChem record; formulation excipients excluded.
A two-dimensional chemical diagram shows bonds and stereochemistry, not a measured three-dimensional shape. PubChem lists HRS-7535 as a synonym of safiglipron; the alias was verified in the downloaded synonyms record.
